Mind the gap in kidney care: translating what we know into what we do.
Chronic kidney disease
Equity
Kidney care
Public health
World Kidney Day
Journal
Clinical and experimental nephrology
ISSN: 1437-7799
Titre abrégé: Clin Exp Nephrol
Pays: Japan
ID NLM: 9709923
Informations de publication
Date de publication:
06 Jul 2024
06 Jul 2024
Historique:
accepted:
13
05
2024
medline:
6
7
2024
pubmed:
6
7
2024
entrez:
6
7
2024
Statut:
aheadofprint
Résumé
Historically, it takes an average of 17 years to move new treatments from clinical evidence to daily practice. Given the highly effective treatments now available to prevent or delay kidney disease onset and progression, this is far too long. The time is now to narrow the gap between what we know and what we do. Clear guidelines exist for the prevention and management of common risk factors for kidney disease, such as hypertension and diabetes, but only a fraction of people with these conditions worldwide are diagnosed, and even fewer are treated to target. Similarly, the vast majority of people living with kidney disease are unaware of their condition, because in the early stages, it is often silent. Even among patients who have been diagnosed, many do not receive appropriate treatment for kidney disease. Considering the serious consequences of kidney disease progression, kidney failure, or death, it is imperative that treatments are initiated early and appropriately. Opportunities to diagnose and treat kidney disease early must be maximized beginning at the primary care level. Many systematic barriers exist, ranging from patient to clinician to health systems to societal factors. To preserve and improve kidney health for everyone everywhere, each of these barriers must be acknowledged so that sustainable solutions are developed and implemented without further delay.
Identifiants
pubmed: 38970648
doi: 10.1007/s10157-024-02518-2
pii: 10.1007/s10157-024-02518-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Investigateurs
Alessandro Balducci
(A)
Vassilios Liakopoulos
(V)
Li-Li Hsiao
(LL)
Ricardo Correa-Rotter
(R)
Ifeoma Ulasi
(I)
Latha Kumaraswami
(L)
Siu Fai Lui
(SF)
Dina Abdellatif
(D)
Ágnes Haris
(Á)
Informations de copyright
© 2024. The Author(s).
Références
Jager KJ, Kovesdy C, Langham R, et al. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Kidney Int. 2019;96:1048–50.
pubmed: 31582227
doi: 10.1016/j.kint.2019.07.012
Institute for Health Metrics and Evaluation (IHME). GBD compare data visualization. http://vizhub.healthdata.org/gbd-compare . Accessed Nov 18 2023
Luyckx VA, Tonelli M, Stanifer JW. The global burden of kidney disease and the sustainable development goals. Bull World Health Organ. 2018;96:414-422D.
pubmed: 29904224
pmcid: 5996218
doi: 10.2471/BLT.17.206441
International Society of Nephrology. ISN Global Kidney Health Atlas, 3rd ed. https://www.theisn.org/initiatives/global-kidney-health-atlas/ . Accessed Nov 18 2023
GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395:709–33.
doi: 10.1016/S0140-6736(20)30045-3
Vanholder R, Annemans L, Brown E, et al. Reducing the costs of chronic kidney disease while delivering quality health care: a call to action. Nat Rev Nephrol. 2017;13:393–409.
pubmed: 28555652
doi: 10.1038/nrneph.2017.63
Nguyen-Thi HY, Le-Phuoc TN, Tri Phat N, et al. The economic burden of chronic kidney disease in Vietnam. Health Serv Insights. 2021. https://doi.org/10.1177/11786329211036011 .
doi: 10.1177/11786329211036011
pubmed: 34376990
pmcid: 8323416
US Renal Data System. Healthcare expenditures for persons with CKD. https://usrds-adr.niddk.nih.gov/2023/chronic-kidney-disease/6-healthcare-expenditures-for-persons-with-ckd . Accessed 31 Sept 2023.
Kidney Health Australia. Transforming Australia’s kidney health: a call to action for early detection and treatment of chronic kidney disease. https://kidney.org.au/uploads/resources/Changing-the-CKD-landscape-Economic-benefits-of-early-detection-and-treatment.pdf . Accessed Jan 16 2024
Ke C, Liang J, Liu M, et al. Burden of chronic kidney disease and its risk-attributable burden in 137 low-and middle-income countries, 1990–2019: results from the global burden of disease study 2019. BMC Nephrol. 2022;23:17.
pubmed: 34986789
pmcid: 8727977
doi: 10.1186/s12882-021-02597-3
Gregg EW, Buckley J, Ali MK, et al. Improving health outcomes of people with diabetes: target setting for the WHO Global Diabetes Compact. Lancet. 2023;401:1302–12.
pubmed: 36931289
pmcid: 10420388
doi: 10.1016/S0140-6736(23)00001-6
Geldsetzer P, Manne-Goehler J, Marcus ME, et al. The state of hypertension care in 44 low-income and middle-income countries: a cross-sectional study of nationally representative individual-level data from 1.1 million adults. Lancet. 2019;394:652–62.
pubmed: 31327566
doi: 10.1016/S0140-6736(19)30955-9
Chu L, Bhogal SK, Lin P, et al. AWAREness of diagnosis and treatment of Chronic Kidney Disease in adults with Type 2 diabetes (AWARE-CKD in T2D). Can J Diabetes. 2022;46:464–72.
pubmed: 35739044
doi: 10.1016/j.jcjd.2022.01.008
Levin A, Tonelli M, Bonventre J, et al. Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. Lancet. 2017;390:1888–917.
pubmed: 28434650
doi: 10.1016/S0140-6736(17)30788-2
Stengel B, Muenz D, Tu C, et al. Adherence to the kidney disease: improving global outcomes CKD guideline in nephrology practice across countries. Kidney Int Rep. 2021;6:437–48.
pubmed: 33615069
doi: 10.1016/j.ekir.2020.11.039
Chu CD, Chen MH, McCulloch CE, et al. Patient awareness of CKD: a systematic review and meta-analysis of patient-oriented questions and study setting. Kidney Med. 2021;3:576-585.e1.
pubmed: 34401725
pmcid: 8350814
doi: 10.1016/j.xkme.2021.03.014
Ene-Iordache B, Perico N, Bikbov B, et al. Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): a cross-sectional study. Lancet Global Health. 2016;4:e307–19.
pubmed: 27102194
doi: 10.1016/S2214-109X(16)00071-1
Gummidi B, John O, Ghosh A, et al. A systematic study of the prevalence and risk factors of CKD in Uddanam. India Kidney Int Rep. 2020;5:2246–55.
pubmed: 33305118
Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;102(5S):S1–127.
Nicholas SB, Daratha KB, Alicic RZ, et al. Prescription of guideline-directed medical therapies in patients with diabetes and chronic kidney disease from the CURE-CKD Registry, 2019–2020. Diabetes Obes Metab. 2023;25:2970–9.
pubmed: 37395334
doi: 10.1111/dom.15194
Grams ME, Yang W, Rebholz CM, et al. Risks of adverse events in advanced CKD: the chronic renal insufficiency cohort (CRIC) study. Am J Kidney Dis. 2017;70:337–46.
pubmed: 28366517
pmcid: 5572665
doi: 10.1053/j.ajkd.2017.01.050
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO. Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024. https://doi.org/10.1016/j.kint.2023.10.018 .
doi: 10.1016/j.kint.2023.10.018
Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2021;99(3S):S1–87.
Tuttle KR, Alicic RZ, Duru OK, et al. Clinical characteristics of and risk factors for chronic kidney disease among adults and children: an analysis of the CURE-CKD registry. JAMA Netw Open. 2019. https://doi.org/10.1001/jamanetworkopen.2019.18169 .
doi: 10.1001/jamanetworkopen.2019.18169
pubmed: 31860111
pmcid: 6991307
Ismail WW, Witry MJ, Urmie JM. The association between cost sharing, prior authorization, and specialty drug utilization: a systematic review. J Manag Care Spec Pharm. 2023;29:449–63.
pubmed: 37121255
Heerspink HJL, Vart P, Jongs N, et al. Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: a joint analysis of randomized controlled clinical trials. Diabetes Obes Metab. 2023;25:3327–36.
pubmed: 37580309
doi: 10.1111/dom.15232
Nuffield Department of Population Health Renal Studies Group. SGLT2 inhibitor meta-analysis cardio-renal trialists’ consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400:1788–801.
doi: 10.1016/S0140-6736(22)02074-8
Fernández-Fernandez B, Sarafidis P, Soler MJ, et al. EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors. Clin Kidney J. 2023;16:1187–98.
pubmed: 37529652
pmcid: 10387399
doi: 10.1093/ckj/sfad082
McEwan P, Boyce R, Sanchez JJG, et al. Extrapolated longer-term effects of the DAPA-CKD trial: a modelling analysis. Nephrol Dial Transpl. 2023;38:1260–70.
doi: 10.1093/ndt/gfac280
Vanholder R, Annemans L, Braks M, et al. Inequities in kidney health and kidney care. Nat Rev Nephrol. 2023;19:694–708.
pubmed: 37580571
doi: 10.1038/s41581-023-00745-6
Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43:474–84.
pubmed: 35023547
doi: 10.1093/eurheartj/ehab777
Tuttle KR, Bosch-Traberg H, Cherney DZI, et al. Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo. Kidney Int. 2023;103:772–81.
pubmed: 36738891
doi: 10.1016/j.kint.2022.12.028
Rubin R. It takes an average of 17 years for evidence to change practice-the burgeoning field of implementation science seeks to speed things up. JAMA. 2023;329:1333–6.
pubmed: 37018006
doi: 10.1001/jama.2023.4387
World Health Organisation. Mid-point evaluation of the implementation of the WHO global action plan for the prevention and control of noncommunicable diseases 2013–2020 (NCD-GAP). https://cdn.who.int/media/docs/default-source/documents/about-us/evaluation/ncd-gap-final-report.pdf?sfvrsn=55b22b89_5&download=true . Accessed Nov 18 2023
Kruk ME, Gage AD, Joseph NT, et al. Mortality due to low-quality health systems in the universal health coverage era: a systematic analysis of amenable deaths in 137 countries. Lancet. 2018;392:2203–12.
pubmed: 30195398
pmcid: 6238021
doi: 10.1016/S0140-6736(18)31668-4
Kingori P, Peeters Grietens K, Abimbola S, et al. Uncertainties about the quality of medical products globally: lessons from multidisciplinary research. BMJ Glob Health. 2023. https://doi.org/10.1136/bmjgh-2023-012902 .
doi: 10.1136/bmjgh-2023-012902
pubmed: 37344004
pmcid: 10367018
Pan American Health Organization Quality control of medicines. https://www.paho.org/en/topics/quality-control-medicines . Accessed Nov 18 2023
Tuttle KR, Wong L, St Peter W, et al. Moving from evidence to implementation of breakthrough therapies for diabetic kidney disease. Clin J Am Soc Nephrol. 2022;17:1092–103.
pubmed: 35649722
pmcid: 9269635
doi: 10.2215/CJN.02980322
Kalyesubula R, Conroy AL, Calice-Silva V, et al. Screening for kidney disease in low- and middle-income countries. Semin Nephrol. 2022. https://doi.org/10.1016/j.semnephrol.2023.151315 .
doi: 10.1016/j.semnephrol.2023.151315
pubmed: 37001337
Francis A, Abdul Hafidz MI, Ekrikpo UE, et al. Barriers to accessing essential medicines for kidney disease in low- and lower middle-income countries. Kidney Int. 2022;102:969–73.
pubmed: 36044940
doi: 10.1016/j.kint.2022.07.029
Rangaswami J, Tuttle K, Vaduganathan M. Cardio-renal-metabolic care models: toward achieving effective interdisciplinary care. Circ Cardiovasc Qual Outcomes. 2020. https://doi.org/10.1161/CIRCOUTCOMES.120.007264 .
doi: 10.1161/CIRCOUTCOMES.120.007264
pubmed: 33176463
Neumiller JJ, Alicic RZ, Tuttle KR. Overcoming barriers to implementing new therapies for diabetic kidney disease: lessons learned. Adv Chronic Kidney Dis. 2021;28:318–27.
pubmed: 34922688
doi: 10.1053/j.ackd.2021.02.001
Mishra SR, Neupane D, Preen D, et al. Mitigation of non-communicable diseases in developing countries with community health workers. Global Health. 2015;11:43.
pubmed: 26555199
pmcid: 4641398
doi: 10.1186/s12992-015-0129-5
Joshi R, John O, Jha V. The potential impact of public health interventions in preventing kidney disease. Semin Nephrol. 2017;37:234–44.
pubmed: 28532553
doi: 10.1016/j.semnephrol.2017.02.004
Patel A, Praveen D, Maharani A, et al. Association of multifaceted mobile technology-enabled primary care intervention with cardiovascular disease risk management in rural Indonesia. JAMA Cardiol. 2019;4:978–86.
pubmed: 31461123
pmcid: 6714032
doi: 10.1001/jamacardio.2019.2974
Ardavani A, Curtis F, Khunti K, et al. The effect of pharmacist-led interventions on the management and outcomes in chronic kidney disease (CKD): a systematic review and meta-analysis protocol. Health Sci Rep. 2023. https://doi.org/10.1002/hsr2.1064 .
doi: 10.1002/hsr2.1064
pubmed: 36660259
pmcid: 9840059
Sherrod CF, Farr SL, Sauer AJ. Overcoming treatment inertia for patients with heart failure: how do we build systems that move us from rest to motion? Eur Heart J. 2023;44:1970–2.
pubmed: 37042346
doi: 10.1093/eurheartj/ehad169
Ramakrishnan C, Tan NC, Yoon S, et al. Healthcare professionals’ perspectives on facilitators of and barriers to CKD management in primary care: a qualitative study in Singapore clinics. BMC Health Services Res. 2022;22:560.
doi: 10.1186/s12913-022-07949-9
Porter J, Boyd C, Skandari MR, et al. Revisiting the time needed to provide adult primary care. J Gen Intern Med. 2023;38:147–55.
pubmed: 35776372
doi: 10.1007/s11606-022-07707-x
Peralta CA, Livaudais-Toman J, Stebbins M, et al. Electronic decision support for management of CKD in primary care: a pragmatic randomized trial. Am J Kidney Dis. 2020;76:636–44.
pubmed: 32682696
pmcid: 7606321
doi: 10.1053/j.ajkd.2020.05.013
Rios P, Sola L, Ferreiro A, et al. Adherence to multidisciplinary care in a prospective chronic kidney disease cohort is associated with better outcomes. PLoS ONE. 2022. https://doi.org/10.1371/journal.pone.0266617 .
doi: 10.1371/journal.pone.0266617
pubmed: 36538525
pmcid: 9767335
Stevenson JK, Campbell ZC, Webster AC, et al. eHealth interventions for people with chronic kidney disease. Cochrane Database Syst Rev. 2019. https://doi.org/10.1002/14651858.CD012379.pub2 .
doi: 10.1002/14651858.CD012379.pub2
pubmed: 31425608
pmcid: 6699665
Tuot DS, Crowley ST, Katz LA, et al. Usability testing of the kidney score platform to enhance communication about kidney disease in primary care settings: qualitative think-aloud study. JMIR Form Res. 2022;6:e40001.
pubmed: 36170008
pmcid: 9557760
doi: 10.2196/40001
Verberne WR, Stiggelbout AM, Bos WJW, et al. Asking the right questions: towards a person-centered conception of shared decision-making regarding treatment of advanced chronic kidney disease in older patients. BMC Med Ethics. 2022;23:47.
pubmed: 35477488
pmcid: 9047263
doi: 10.1186/s12910-022-00784-x
Taha A, Iman Y, Hingwala J, et al. Patient navigators for CKD and kidney failure: a systematic review. Kidney Med. 2022. https://doi.org/10.1016/j.xkme.2022.100540 .
doi: 10.1016/j.xkme.2022.100540
pubmed: 36185707
pmcid: 9516458
Essue BM, Laba M, Knaul F, et al. Economic burden of chronic ill health and injuries for households in low- and middle-income countries. In: Jamison DT, Gelband H, Horton S, et al., editors. Disease control priorities: improving health and reducing poverty 3rd ed. Washington DC: The International Bank for Reconstruction and Development/The World Bank; 2017.
Khatib R, McKee M, Shannon H, et al. Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data. Lancet. 2016;387:61–9.
pubmed: 26498706
doi: 10.1016/S0140-6736(15)00469-9
Kamath N, Iyengar AA. Chronic kidney disease (CKD): an observational study of etiology, severity and burden of comorbidities. Indian J Pediatr. 2017;84:822–5.
pubmed: 28711960
doi: 10.1007/s12098-017-2413-2
Cirillo L, Ravaglia F, Errichiello C, et al. Expectations in children with glomerular diseases from SGLT2 inhibitors. Pediatr Nephrol. 2022;37:2997–3008.
pubmed: 35286452
doi: 10.1007/s00467-022-05504-6
Donohue JF, Elborn JS, Lansberg P, et al. Bridging the “know-do” gaps in five non-communicable diseases using a common framework driven by implementation science. J Healthc Leadersh. 2023;15:103–19.
pubmed: 37416849
pmcid: 10320809
doi: 10.2147/JHL.S394088
Population Health Research Institute. Polypills added to WHO essential medicines list. https://www.phri.ca/eml/ . Accessed Nov 18 2023
Sepanlou SG, Mann JFE, Joseph P, et al. Fixed-dose combination therapy for prevention of cardiovascular diseases in CKD: an individual participant data meta-analysis. Clin J Am Soc Nephrol. 2023;18:1408–15.
pubmed: 37550842
doi: 10.2215/CJN.0000000000000251
Dev V, Mittal A, Joshi V, et al. Cost analysis of telemedicine use in paediatric nephrology-the LMIC perspective. Pediatr Nephrol. 2024;39:193–201.
pubmed: 37488241
doi: 10.1007/s00467-023-06062-1
Musacchio N, Zilich R, Ponzani P, et al. Transparent machine learning suggests a key driver in the decision to start insulin therapy in individuals with type 2 diabetes. J Diabetes. 2023;15:224–36.
pubmed: 36889912
pmcid: 10036260
doi: 10.1111/1753-0407.13361
Zuniga C, Riquelme C, Muller H, et al. Using telenephrology to improve access to nephrologist and global kidney management of CKD primary care patients. Kidney Int Rep. 2020;5:920–3.
pubmed: 32518875
pmcid: 7270717
doi: 10.1016/j.ekir.2020.03.002
van der Horst DEM, Hofstra N, van Uden-Kraan CF, et al. Shared decision making in health care visits for CKD: patients’ decisional role preferences and experiences. Am J Kidney Dis. 2023;82:677–86.
pubmed: 37516297
doi: 10.1053/j.ajkd.2023.04.012
Hole B, Scanlon M, Tomson C. Shared decision making: a personal view from two kidney doctors and a patient. Clin Kidney J. 2023;16:i12–9.
pubmed: 37711639
pmcid: 10497374
doi: 10.1093/ckj/sfad064